Loading...
Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC.
Pellegrino, Rossella Thavamani, Abhishek Calvisi, Diego F Budczies, Jan Neumann, Ariane Geffers, Robert Kroemer, Jasmin Greule, Damaris Schirmacher, Peter Nordheim, Alfred
Pellegrino, Rossella
Thavamani, Abhishek
Calvisi, Diego F
Budczies, Jan
Neumann, Ariane
Geffers, Robert
Kroemer, Jasmin
Greule, Damaris
Schirmacher, Peter
Nordheim, Alfred
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-01-08
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 5.85 MB
Other Titles
Abstract
Different molecular mechanisms support the overexpression of the mouse double minute homolog 4 (MDM4), a functional p53 inhibitor, in human hepatocellular carcinoma (HCC). However, the transcription factors (TFs) leading to its transcriptional upregulation remain unknown. Following promoter and gene expression analyses, putative TFs were investigated using gene-specific siRNAs, cDNAs, luciferase reporter assays, chromatin immunoprecipitation, and XI-011 drug treatment in vitro. Additionally, MDM4 expression was investigated in SRF-VP16iHep transgenic mice. We observed a copy-number-independent upregulation of MDM4 in human HCCs. Serum response factor (SRF), ELK1 and ELK4 were identified as TFs activating MDM4 transcription. While SRF was constitutively detected in TF complexes at the MDM4 promoter, presence of ELK1 and ELK4 was cell-type dependent. Furthermore, MDM4 was upregulated in SRF-VP16-driven murine liver tumors. The pharmacological inhibitor XI-011 exhibited anti-MDM4 activity by downregulating the TFs driving MDM4 transcription, which decreased HCC cell viability and increased apoptosis. In conclusion, SRF drives transcriptional MDM4 upregulation in HCC, acting in concert with either ELK1 or ELK4. The transcriptional regulation of MDM4 may be a promising target for precision oncology of human HCC, as XI-011 treatment exerts anti-MDM4 activity independent from the MDM4 copy number and the p53 status.
Citation
Cancers (Basel). 2021 Jan 8;13(2):199. doi: 10.3390/cancers13020199.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
2072-6694
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International